Celcuity Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CELC Nasdaq 8731 http://celcuity.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celcuity Inc

Celcuity Inc. (NASDAQ:CELC) Q4 2022 Earnings Call Transcript - Mar 27th, 2023 6:43 am
Q4 2022 Celcuity Inc Earnings Call - Mar 24th, 2023 11:07 am
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Mar 23rd, 2023 8:00 pm
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call - Mar 16th, 2023 12:00 pm
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 - Mar 15th, 2023 11:35 pm
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference - Mar 1st, 2023 1:00 pm
While institutions own 25% of Celcuity Inc. (NASDAQ:CELC), individual investors are its largest shareholders with 58% ownership - Feb 17th, 2023 10:07 am
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium - Feb 16th, 2023 1:00 pm
Insiders pour millions into these 3 stocks — this is what makes them attractive buys - Dec 18th, 2022 9:38 am
Bullish insiders bet US$1.6m on Celcuity Inc. (NASDAQ:CELC) - Dec 15th, 2022 10:59 am
Celcuity Closes $100 Million Private Placement - Dec 12th, 2022 12:30 pm
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium - Dec 9th, 2022 1:40 pm
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer - Dec 7th, 2022 9:00 pm
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium - Nov 22nd, 2022 12:30 pm
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference - Nov 10th, 2022 9:30 pm
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 10th, 2022 9:00 pm
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call - Nov 3rd, 2022 12:50 pm
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors - Sep 14th, 2022 1:00 pm
What Is The Ownership Structure Like For Celcuity Inc. (NASDAQ:CELC)? - Aug 15th, 2022 1:39 pm
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Aug 11th, 2022 8:00 pm